NASDAQ:HTBX
Delisted
Heat Biologics Stock News
$2.38
+0 (+0%)
At Close: Aug 17, 2022
Heat Biologics, Inc. (NASDAQ:HTBX) Analysts Just Slashed This Year's Revenue Estimates By 12%
01:07pm, Thursday, 30'th Jul 2020
The latest analyst coverage could presage a bad day for Heat Biologics, Inc. (NASDAQ:HTBX), with the analysts making...
Why Heat Biologics Stock Is Spiking Today
04:05pm, Wednesday, 29'th Jul 2020
Heat Biologics (NASDAQ: HTBX), a prerevenue biotech, is off to a strong start today. Specifically, Heat announced that its COVID-19 vaccine candidate exhibited compelling evidence of immunogenicity (
Heat Biologics COVID-19 Vaccine Demonstrates Immunogenicity Proof-of-Concept in Pre-Clinical Studies
11:30am, Wednesday, 29'th Jul 2020
Confirms stimulation of human-HLA-restricted transgenic mouse T-cells against immunodominant epitopes of SARS-CoV-2 Spike proteinDURHAM, NC / ACCESSWIRE / July 29, 2020 / Heat Biologics, Inc.
Heat Biologics Regains Compliance with Nasdaq Minimum Bid Price Rule
10:30am, Monday, 27'th Jul 2020
DURHAM, NC / ACCESSWIRE / July 27, 2020 / Heat Biologics, Inc.
Spectrum Pharmaceuticals Announces Positive Topline Results in HER2 Exon20 Insertion Mutations from Cohort 2 of the Poziotinib ZENITH20 Trial
Advances in Treating Non-Small Cell Lung Cancer
05:00am, Saturday, 25'th Jul 2020
(Family Features) Despite progress in treating lung cancer, it is the leading cause of cancer deaths and impacts communities across the United States. The most common form of lung cancer
2020 Insights into the Cancer Vaccines Market - Pipeline Analysis Report - ResearchAndMarkets.com
12:00am, Wednesday, 22'nd Jul 2020
The
Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-03, a global phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination
Heat Biologics: Diversifying Into COVID Vaccine Research
05:54am, Saturday, 18'th Jul 2020
Heat Biologics is expanding its activities from cancer treatment development to include COVID-19 vaccine research.
Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced two presentations featuring its Bl
Novocure has entered into a clinical trial collaboration agreement with MSD to develop Tumor Treating Fields together with KEYTRUDA® for NSCLC.
EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive Metastatic Breast Cancer
